NCT06867588View on ClinicalTrials.gov

The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)

NARecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Multiparametric MRILesion PI-RADS 3
Interventions
DIAGNOSTIC_TEST

PSMA PET

patients included in the study will perfom a PSMA PET

Trial Locations (1)

1070

RECRUITING

Institut Jules Bordet, Brussels

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER

NCT06867588 - The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA) | Biotech Hunter | Biotech Hunter